Biosergen

Historical price data

Biosergen is a clinical-stage biotechnology company focused on revolutionizing the treatment of invasive fungal diseases (IFDs) through genetic engineering. Its lead asset, BSG005, is a novel polyene antifungal that has demonstrated a superior safety profile in a Phase 1 study, with no significant side effects observed, addressing the critical nephrotoxicity that plagues current standards of care. The company's strategy leverages a proprietary platform to re-engineer polyene macrolides, aiming to capture a significant share of the growing antifungal market driven by rising immunocompromised populations and increasing drug resistance. Biosergen is advancing BSG005 into proof-of-concept studies with a key partnership in India and holds global commercial rights.

A proprietary platform for the genetic engineering of polyene macrolides, enabling the creation of novel antifungal compounds designed to retain broad-spectrum fungicidal activity while eliminating the severe kidney toxicity associated with traditional polyenes.

Competes against toxic but effective polyenes (e.g., amphotericin B), fungistatic azoles with rising resistance, and novel agents with narrower spectrums. BSG005's key differentiator is its potential to be the first safe, broad-spectrum, fungicidal polyene, positioning it as a potential first-line therapy.